Comparative Pharmacology
Head-to-head clinical analysis: CORTISONE ACETATE versus DEXONE 1 5.
Head-to-head clinical analysis: CORTISONE ACETATE versus DEXONE 1 5.
CORTISONE ACETATE vs DEXONE 1.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with glucocorticoid and mineralocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses.
Dexamethasone is a long-acting glucocorticoid receptor agonist that suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
25-300 mg per day orally, in divided doses every 6-12 hours, depending on condition severity.
1.5 mg orally once daily
None Documented
None Documented
30 minutes (plasma half-life of cortisol); biological half-life 8-12 hours (due to intracellular receptor binding and transcriptional effects)
Clinical Note
moderateCortisone acetate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gatifloxacin."
Clinical Note
moderateCortisone acetate + Rosoxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rosoxacin."
Clinical Note
moderateCortisone acetate + Levofloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life approximately 3-4 hours (dexamethasone), with clinical effects persisting 36-54 hours due to glucocorticoid receptor-mediated actions.
Renal (approximately 90% as metabolites, <5% unchanged); biliary/fecal (<5%)
Renal (primarily as metabolites, ~60%), biliary/fecal (~30%), with <5% excreted unchanged.
Category C
Category C
Corticosteroid
Corticosteroid
Cortisone acetate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Trovafloxacin."